ID 415102490 · FY 2018–2024 · 7 years
Gold Pharma (გოლდ ფარმა) — a Georgian pharmaceutical goods trader/distributor (revenue ~GEL 6.5m, cost-of-goods-bearing, gross margin ~42%). NOTE: its balance sheet looks anomalous — trade receivables of ~GEL 48.5m (≈7.5× annual revenue and almost the entire asset base) with negligible cash and inventory — likely a related-party/financing pile-up or a reporting error, so its asset-based ratios (ROA/ROE) should not be trusted.
curated 2026-06-25
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,224 | 11,562 | 13,354 | 6,049 | 5,158 | 8,055 | 6,513 | +12.4% |
| Total COGS | -1,653 | -4,500 | -3,116 | -2,344 | -3,062 | -4,294 | -3,805 | +14.9% |
| Gross Profit | 1,570 | 7,063 | 10,238 | 3,706 | 2,096 | 3,761 | 2,708 | +9.5% |
| Gross Margin | 48.7% | 61.1% | 76.7% | 61.3% | 40.6% | 46.7% | 41.6% | |
| Total Operating Expenses | -36 | -165 | -1,341 | -1,451 | -192 | -199 | -183 | +31.4% |
| EBITDA | 1,535 | 6,898 | 8,897 | 2,255 | 1,904 | 3,561 | 2,525 | +8.7% |
| EBITDA Margin | 47.6% | 59.7% | 66.6% | 37.3% | 36.9% | 44.2% | 38.8% | |
| Total D&A | 0 | 0 | 0 | 0 | 0 | 0 | -7 | |
| EBIT / Operating Income | 1,535 | 6,898 | 8,897 | 2,255 | 1,904 | 3,561 | 2,518 | +8.6% |
| Total Interest Expense | -17 | -67 | -76 | -82 | -81 | -61 | -61 | +23.7% |
| Total Other Income | -15 | 302 | 1,825 | 1,437 | -2,742 | 0 | 1,413 | nmf |
| Profit Before Tax | 1,502 | 7,133 | 10,647 | 3,610 | -919 | 3,500 | 3,869 | +17.1% |
| Total Income Tax | -0 | -1 | -0 | 0 | 0 | 0 | 0 | nmf |
| Net Profit / (Loss) | 1,519 | 7,199 | 8,897 | 2,255 | -838 | 3,561 | 3,938 | +17.2% |
| Net Margin | 47.1% | 62.3% | 66.6% | 37.3% | -16.2% | 44.2% | 60.5% |
Ownership & directors from companyinfo.ge (public corporate registry).